Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

NCT01862328 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: MLN4924
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Carboplatin

Sponsor

Millennium Pharmaceuticals, Inc.